All Trials

Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent supratentorial glioblastoma after prior chemoradiation and maximal safe resection are randomized to lerapolturev (PVSRIPO)—an intratumoral/oncolytic poliovirus-rhinovirus chimera targeting CD155 with proposed oncolysis and innate/T-cell immune activation—given via two postoperative CED infusions plus serial cervical perilymphatic SC injections, versus standard lomustine. Key exclusions include infratentorial/leptomeningeal disease, high steroid requirement, and lack of polio vaccination/booster.

ClinicalTrials.gov ID: NCT06177964

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling patients ≥10 years (≥30 kg) with unresectable/metastatic solid tumors or recurrent/progressive primary CNS tumors harboring qualifying BRAF alterations (class 1 V600E or class 2 incl. fusions), across cohorts for BRAF fusions, V600E CNS tumors, and selected rare V600E non‑CNS tumors; excludes NF1/activating RAS and prior MAPK inhibitors in most cohorts. Treatment is oral plixorafenib (PLX‑8394), a selective BRAF inhibitor that disrupts RAF dimer signaling and avoids paradoxical ERK activation, given alone or with cobicistat boosting depending on cohort.

ClinicalTrials.gov ID: NCT05503797

A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent or metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx, including p16/HPV+ unknown primary) after prior PD-1/PD-L1 therapy receive the CHK1/2 inhibitor ACR-368 (prexasertib) plus ultra–low-dose gemcitabine every 2 weeks, with separate cohorts by p16/HPV status. Requires measurable disease, ECOG 0–1, recent tissue for p16/HPV and OncoSignature, and biopsy willingness; key toxicities expected are transient high-grade myelosuppression.

ClinicalTrials.gov ID: NCT06597565

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adult women with platinum‑resistant or refractory high‑grade serous ovarian, fallopian tube, or primary peritoneal cancer (measurable disease, ECOG 0–1) after at least one prior platinum regimen, randomized to CBX‑12 IV every 21 days at 100 vs 125 mg/m². CBX‑12 (alphalex exatecan) is a peptide–drug conjugate that targets acidic tumor microenvironments via pH‑low insertion peptide to deliver a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06315491

Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum‑resistant high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1) are randomized to ubamatamab (MUC16×CD3 T‑cell–redirecting bispecific) with prophylactic sarilumab, given alone or combined with bevacizumab, cemiplimab plus fianlimab (PD‑1/LAG‑3 blockade), or pegylated liposomal doxorubicin. Excludes clear cell/mucinous/carcinosarcoma histologies and active CNS disease; primary endpoint is RECIST ORR.

ClinicalTrials.gov ID: NCT06787612

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with platinum‑resistant high‑grade serous ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) receive oral azenosertib (ZN‑c3), a selective WEE1 kinase inhibitor, as monotherapy on an intermittent schedule; Part 2 enrolls centrally confirmed Cyclin E1–positive tumors with dose selection (300 vs 400 mg) then expansion at the chosen dose. Prior bevacizumab and PARP inhibitor (if eligible) are required, with exclusions for primary platinum‑refractory disease and prior WEE1/ATR/PKMYT1/CHK1/2 inhibitors.

ClinicalTrials.gov ID: NCT05128825

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (serous/endometrioid/clear cell), platinum-sensitive or -resistant, ≤3 prior lines, measurable disease, and ECOG 0–1 are randomized to pembrolizumab plus bevacizumab with or without CDX-1140. CDX-1140 is an investigational agonist anti-CD40 antibody intended to activate dendritic/B cells and augment T-cell antitumor responses.

ClinicalTrials.gov ID: NCT05231122

Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent, advanced platinum-resistant or platinum-ineligible high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) receive oral 2X-121 (stenoparib), a dual PARP1/2 and tankyrase 1/2 inhibitor, as monotherapy at either 600 mg/day or 800 mg/day. The study compares dosing to optimize safety, PK/PD, and antitumor activity; prior ADCs allowed and no more than one prior line in the platinum-resistant/ineligible setting.

ClinicalTrials.gov ID: NCT03878849

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Women with platinum-resistant or refractory high‑grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, prior bevacizumab, ≥3 prior lines, measurable peritoneal disease) are randomized to intraperitoneal olvimulogene nanivacirepvec (oncolytic vaccinia immunotherapy) followed by platinum-doublet chemotherapy plus bevacizumab versus physician’s choice chemotherapy plus bevacizumab. Investigational Olvi‑Vec is designed to selectively replicate in tumor cells to induce oncolysis and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT05281471

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic cutaneous (including acral) melanoma who are HLA‑A*02:01 positive and have progressed after PD‑1 therapy (and BRAF‑directed therapy if mutated) are randomized to autologous PRAME‑targeted TCR‑T cells (IMA203) after lymphodepletion with short-course low‑dose IL‑2 support versus investigator’s choice of approved therapies (e.g., nivolumab/relatlimab, anti‑PD‑1, ipilimumab, lifileucel, or chemotherapy). Key exclusions include mucosal/uveal melanoma, active CNS disease, significant autoimmune/cardiac comorbidities, active infections, and LDH >2× ULN.

ClinicalTrials.gov ID: NCT06743126